

Laura van Dussen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5525172/publications.pdf>

Version: 2024-02-01

14
papers

700
citations

759233

12
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

899
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5784. | 4.1 | 9 |
| 2 | Hepatocellular carcinoma in Gaucher disease: an international case series. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 819-827. | 3.6 | 37 |
| 3 | Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 1259-1265. | 3.6 | 7 |
| 4 | Lung Transplantation in Gaucher Disease. <i>Chest</i> , 2016, 149, e1-e5. | 0.8 | 16 |
| 5 | Short-Term Effect of Estrogen on Human Bone Marrow Fat. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2058-2066. | 2.8 | 61 |
| 6 | Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. <i>British Journal of Haematology</i> , 2013, 161, 832-842. | 2.5 | 98 |
| 7 | Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage. <i>PLoS ONE</i> , 2013, 8, e57507. | 2.5 | 45 |
| 8 | Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. <i>Haematologica</i> , 2012, 97, 1850-1854. | 3.5 | 15 |
| 9 | Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. <i>British Journal of Haematology</i> , 2012, 158, 528-538. | 2.5 | 33 |
| 10 | Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. <i>Blood</i> , 2011, 118, e118-e127. | 1.4 | 224 |
| 11 | Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 44, 41-47. | 1.4 | 88 |
| 12 | Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 44, 181-187. | 1.4 | 14 |
| 13 | Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose-response relationships. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2641-2652. | 1.8 | 22 |
| 14 | Gaucher disease: a model disorder for biomarker discovery. <i>Expert Review of Proteomics</i> , 2009, 6, 411-419. | 3.0 | 31 |